Search

everythinglearnresearchcommunity

for

Search:↓

Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.

A transwoman is struggling with hair loss despite using hormones, dutasteride, and Abiraterone, and is considering making her own treatments due to difficulty accessing them. She has also tried Eucapil and regularly uses Nizoral shampoo.

The conversation is about acquiring GT20029 for hair loss treatment. The user is looking for information on how to obtain it.

ET-02, a PAI-1 inhibitor, is not proven to be more effective than Minoxidil for hair loss. Other treatments like finasteride, dutasteride, PP405, and AMP-303 are also discussed, focusing on cellular senescence and oxidative stress.

Dutasteride is associated with increased blood glucose, HbA1c, LDL cholesterol, and liver enzyme activity, potentially leading to diabetes, NAFLD, and liver metabolism changes. The conversation highlights concerns about these adverse effects and calls for more studies, including on finasteride.

The user experienced positive hair regrowth using daily 1mg finasteride and 5% minoxidil, specifically the Alopexy brand, with no negative side effects. They noticed improvements after a year, with comments from others confirming the success.

The user is experiencing an itchy scalp and acne while using oral dutasteride and minoxidil for hair loss. They are considering stopping minoxidil to see if symptoms improve and possibly switching to finasteride if needed.

A user is considering mixing 5% topical minoxidil with Alpecin Caffeine Liquid to enhance its effect, while also using oral finasteride. They seek feedback on potential efficacy loss and downsides of this mixture.

A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

The conversation discusses the ineffectiveness of dutasteride in halting hair loss for the user and explores the potential of PP405, which works through a different mechanism. Suggestions include considering a biopsy to determine the cause of hair loss and exploring other treatments like RU58841.

The user is experiencing hair regrowth using finasteride, minoxidil, and KX-826. They regret not starting treatment earlier but are now seeing progress.

User experienced reduced hair loss with 15mg RU in Serioxyl but had concerning chest pain. Others suggested consulting a doctor or lowering the dose.

The conversation discusses potential hair loss treatments, including hair cloning, setipiprant, and topical finasteride, questioning their availability and effectiveness as permanent cures. The user is inquiring about the release dates and efficacy of these treatments.

A 32-year-old male with diffuse thinning and seborrheic dermatitis has been using finasteride for 8 months without improvement. He is considering COQ10 + PQQ supplements for scalp inflammation and hair loss.

Seeking adenosine shampoo or conditioner in the UK without minoxidil. Topical adenosine solution also considered.

PP405 is a potential hair loss treatment that may work by blocking signals that cause hair cells to stop growing, requiring daily application for effectiveness. It could serve as an alternative to minoxidil and finasteride, but it is not yet available on the market and may take several years to be released.

PP405 and hair cloning are discussed as potential treatments for reversing hair loss from Norwood 7 to Norwood 1. Hair cloning is seen as a more permanent solution, while PP405's effectiveness and long-term effects remain uncertain.

The user switched from finasteride to dutasteride for hair loss treatment, also using topical minoxidil, micro needling, keto shampoo, and PRP sessions. They've seen improvements, with reduced hair shedding and new hair growth, especially at the hairline.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

The user started using pyrilutamide for hair loss on January 24, applying 1ml daily without other treatments, and after 10 days noticed reduced hair shedding and improved hair quality, with plans to continue for at least 6 months. They experienced chest pain initially, which could be related to starting methylphenidate or pyrilutamide, but the pain has since subsided.

The conversation discusses using 2-deoxy-d-ribose (2DDR) for hair regrowth, with users sharing mixed experiences and side effects like hair loss in new areas and increased anxiety. The original poster plans to continue testing and comparing it to minoxidil, noting potential instability in 2DDR formulations.

Minoxidil and caffeine may interact, affecting hair growth results. Users shared mixed experiences, with some noticing improvements without caffeine and others still seeing results despite coffee consumption.

The conversation is about someone seeking a doctor in the EU who prescribes spironolactone or bicalutamide for female pattern hair loss, as they are having difficulty finding treatment options beyond Minoxidil in Austria. They are asking for recommendations and are open to direct messages for assistance.

The user is using spironolactone for AGA and is concerned about obtaining it in the U.S. without a prescription. They are seeking advice on how to get a prescription in the U.S. as an immigrant.

The conversation discusses hair loss treatments, specifically mentioning Exosomes, Minoxidil, Finasteride, and RU58841. The user offers $50 gift cards for new Musely customers.

Switching from spironolactone to bicalutamide caused severe hair shedding, despite using treatments like dutasteride, minoxidil, and estradiol injections. The user is experiencing androgenetic alopecia and is seeking solutions to stop the hair loss.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

The conversation discusses sourcing pure latanoprost from the gray market for research and making a homemade solution. Concerns about potential dangers and experiences with this method are raised.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.